The retinoic acid analog CBS-211A potentiates the 1 alpha,25-dihydroxyvitamin D3-induced differentiation of U937 cells.
We report the effect of CBS-211A, a synthetic retinoid analog, designed for topical eye administration, on the growth and differentiation of myelomonocytic cells. This compound was assayed alone or in combination with 1 alpha,25-dihydroxyvitamin D3 (1 alpha,25(OH)2D3), since we previously evidenced a synergism of retinoic acid (RA) and 1 alpha,25(OH)2D3 in the induction of U937 cell differentiation. Unlike RA, CBS-211A neither affected the growth of myelomonocytic cells nor differentiated them. Nevertheless, when it was associated with 1 alpha,25(OH)2D3, CBS-211A strongly potentiated the 1 alpha,25(OH)2D3-induced inhibition of U937 cell proliferation and caused a dramatic increase in their differentiation toward monocytes/macrophages. The co-inducing effect of CBS-211A was restricted to U937 cells. Our data suggest that CBS-211A may have therapeutic implications in the treatment of certain kinds of myelomonocytic leukemia. CBS-211A also provides an interesting tool to understand the mechanisms involved in the differentiation of myelomonocytic cells.
Taimi
M
M
INSERM U65, Département de Biologie-Santé, Université de Montpellier II, France.
Defacque
H
H
Commes
T
T
Favero
J
J
Dornand
J
J
Marti
J
J
D000818:Animals; D015703:Antigens, CD / Q000032:analysis; D001565:Benzoates / Q000494:pharmacology*; D002117:Calcitriol / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004357:Drug Synergism; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism; D008163:Luminescent Measurements; D009000:Monocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D014407:Tumor Cells, Cultured
D015703:Antigens, CD; D001565:Benzoates; D015850:Interleukin-6; C062800:CBS 211 A; D002117:Calcitriol